Laura A Colangelo1, Pamela Ouyang2, Sherita Hill Golden2, Moyses Szklo3, Susan M Gapstur4, Dhananjay Vaidya2, Kiang Liu5. 1. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1400, Chicago, IL 60611, United States. Electronic address: l-colangelo@northwestern.edu. 2. Department of Medicine, Johns Hopkins University, Baltimore, MD, United States. 3. Department of Epidemiology, Johns Hopkins University, Baltimore, MD, United States. 4. Epidemiology Research Program, American Cancer Society, Atlanta, GA, United States. 5. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1400, Chicago, IL 60611, United States.
Abstract
INTRODUCTION: Considering that estradiol (E2) and n-3 polyunsaturated fatty acids (PUFAs) have roles in neurogenesis and in neurotransmission, we examined whether the association of PUFAs with incident depressive symptoms in postmenopausal women is modified by hormone therapy (HT) use or estrogen status. METHODS: Women (N=1616) free of depressive symptoms at baseline (2000-2002) in the Multi-Ethnic Study of Atherosclerosis were classified by HT usage and quartiles of dietary eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and the sum EPA+DHA. Women with serum E2 ≤0.073 nmol/L (sample median), were classified low on E2. Poisson regression was used to model incident depressive symptoms at examination 3 (2004-05), defined by the Center for Epidemiological Studies Depression Scale ≥16 or taking an antidepressant, first as a function of HT use and n-3 PUFA quartiles, and second, as a function of low E2 status and n-3 PUFA quartiles. RESULTS: Among HT non- users, positive, graded relationships (p-trends≤0.003) were found between PUFAs and incident depressive symptoms. Compared to the lowest quartile, the adjusted risk ratios (RRs) for the highest were 2.10, 2.39, and 2.04 for EPA, DHA, and EPA+DHA, respectively. For HT users, no associations were seen. When analyses were run for E2 status, the RRs over quartiles of the PUFAs were positive and graded for low E2 women, but were null for High E2 women. CONCLUSIONS: Higher intakes of DHA and EPA were associated with higher risk of depressive symptoms in nonusers of HT, contrary to hypothesis. Copyright Â
INTRODUCTION: Considering that estradiol (E2) and n-3 polyunsaturated fatty acids (PUFAs) have roles in neurogenesis and in neurotransmission, we examined whether the association of PUFAs with incident depressive symptoms in postmenopausal women is modified by hormone therapy (HT) use or estrogen status. METHODS:Women (N=1616) free of depressive symptoms at baseline (2000-2002) in the Multi-Ethnic Study of Atherosclerosis were classified by HT usage and quartiles of dietary eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and the sum EPA+DHA. Women with serum E2 ≤0.073 nmol/L (sample median), were classified low on E2. Poisson regression was used to model incident depressive symptoms at examination 3 (2004-05), defined by the Center for Epidemiological Studies Depression Scale ≥16 or taking an antidepressant, first as a function of HT use and n-3 PUFA quartiles, and second, as a function of low E2 status and n-3 PUFA quartiles. RESULTS: Among HT non- users, positive, graded relationships (p-trends≤0.003) were found between PUFAs and incident depressive symptoms. Compared to the lowest quartile, the adjusted risk ratios (RRs) for the highest were 2.10, 2.39, and 2.04 for EPA, DHA, and EPA+DHA, respectively. For HT users, no associations were seen. When analyses were run for E2 status, the RRs over quartiles of the PUFAs were positive and graded for low E2 women, but were null for High E2 women. CONCLUSIONS: Higher intakes of DHA and EPA were associated with higher risk of depressive symptoms in nonusers of HT, contrary to hypothesis. Copyright Â
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: Menopause Date: 2012-04 Impact factor: 2.953
Authors: Michel Lucas; Fariba Mirzaei; Eilis J O'Reilly; An Pan; Walter C Willett; Ichiro Kawachi; Karestan Koenen; Alberto Ascherio Journal: Am J Clin Nutr Date: 2011-04-06 Impact factor: 7.045
Authors: Reeta Hakkarainen; Timo Partonen; Jari Haukka; Jarmo Virtamo; Demetrius Albanes; Jouko Lönnqvist Journal: Am J Psychiatry Date: 2004-03 Impact factor: 18.112
Authors: Matthew G Pontifex; Anneloes Martinsen; Rasha N M Saleh; Glenn Harden; Chris Fox; Michael Muller; David Vauzour; Anne-Marie Minihane Journal: Nutrients Date: 2022-04-19 Impact factor: 6.706